SIX : COPN.SW
-$0.8 (-1.26%)
SIX
Giovanni di Napoli
Medical - Pharmaceuticals
Healthcare
COPN.SW
325
IE
CHF
0.01
10.66
10.12
1.25
-6.93
$104.85M
11.29
2.03
-48.67
-1.40
-$0.23
-$3.63M
-6.18%
-3.92%
-1.21%
-0.91%
-177.45
1.73
1.73
2/5
0 Analysts
%
7.44
6/9
$238.62M
$695.64M
$121.91M
$51.32M
No key metrics data available.
| Name | Title |
|---|---|
| Davide Malavasi | Qualified Person & Technical Director |
| Silvia Miliani | Chief HR Officer |
| Svetlana Sigalova | Chief Financial Officer |
| Mauro Severino Ajani | Founder & Non-Executive Director |
| Giovanni Di Napoli | Chief Executive Officer & Director |
| Federico Sommariva | Chief Legal Counsel |
| Luigi Longo | Chief Scientific Officer |
| Ngo Dinh Nhan | President of Cosmo Intelligent Medical Devices |
| Niall Donnelly | Executive Vice President of Corporate Governance, Chief Sustainability Officer & Executive Director |
| Alessandro E. Della Cha | Non Executive Chairman |
No votes yet today — be the first to share your view!
About Cosmo Pharmaceuticals N.V. (SIX:COPN.SW) Stock
Cosmo Pharmaceuticals NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland. ...
2026-07-23 01:01:00
Ad hoc announcement pursuant to Art. 53 LR
Invitation to Cosmo's Half-Year 2026 Financial Results Webcast on 23 July 2026
2026-07-01 01:00:00
Dublin, Ireland--(Newsfile Corp. - July 1, 2026) - Cosmo N.V. (SIX: COPN) ("Cosmo") announced
Cosmo Welcomes the Launch of Winlevi(R) in Key European Markets by Its Partner Glenmark
2026-06-11 01:19:00
Dublin, Ireland--(Newsfile Corp. - June 11, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43) ("Cosmo") is pleased to make known that its
Cosmo Announces Completion of Phase II Enrolment in Distal Ulcerative Colitis Program
2026-05-18 01:03:00
Dublin, Ireland--(Newsfile Corp. - May 18, 2026) - Cosmo N.V. (SIX: COPN) (XETRA: C43)
Frequently Asked Questions
What is the current Cosmo Pharmaceuticals N.V. (COPN.SW) stock price?
Cosmo Pharmaceuticals N.V.(SIX:COPN.SW) stock price is $62.8 in the last trading session. During the trading session, COPN.SW stock reached the peak price of $129.4 while $53.4 was the lowest point it dropped to. The percentage change in COPN.SW stock occurred in the recent session was --1.26% while the dollar amount for the price change in COPN.SW stock was -$0.8.
COPN.SW's industry and sector of operation?
The SIX listed COPN.SW is part of Medical - Pharmaceuticals industry that operates in the broader Healthcare sector.
Who are the executives of COPN.SW?
Davide Malavasi
| Qualified Person & Technical Director
Silvia Miliani
| Chief HR Officer
Svetlana Sigalova
| Chief Financial Officer
Mauro Severino Ajani
| Founder & Non-Executive Director
Giovanni Di Napoli
| Chief Executive Officer & Director
How many employees does COPN.SW have?
Number of COPN.SW employees currently stands at 325. COPN.SW operates from 11, rue de Langallerie, Dublin, DU 1003, IE.
Link for COPN.SW official website?
Official Website of COPN.SW is: http://www.cosmopharma.com
How do I contact COPN.SW?
COPN.SW could be contacted at phone #353 1 817 0370 and can also be accessed through its website. COPN.SW operates from 11, rue de Langallerie, Dublin, DU 1003, IE.
How many shares of COPN.SW are traded daily?
The average number of COPN.SW shares traded daily for last 3 months was 37.06K.
What is the market cap of COPN.SW currently?
The market value of COPN.SW currently stands at $1.08B with its latest stock price at $62.8